About the Authors
- Samir Attoub
-
* E-mail: samir.attoub@uaeu.ac.ae
Affiliation Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates
- Kholoud Arafat
-
Affiliation Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates
- An Gélaude
-
Affiliation Laboratory of Experimental Cancer Research, University Hospital, Gent, Belgium
- Mahmood Ahmed Al Sultan
-
Affiliation Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates
- Marc Bracke
-
Affiliation Laboratory of Experimental Cancer Research, University Hospital, Gent, Belgium
- Peter Collin
-
Affiliation Coastside Bio Resources, Stonington, Maine, United States of America
- Takashi Takahashi
-
Affiliation Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Thomas E. Adrian
-
Affiliation Department of Physiology, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates
- Olivier De Wever
-
Affiliation Laboratory of Experimental Cancer Research, University Hospital, Gent, Belgium
Competing Interests
Peter Collin is director, laboratory manager, employee and stock-holder of Coastside Bio Resources, a Maine, USA Corporation. Thomas Adrian and Peter Collin are co-inventors of a United States patent describing Frondoside A and other sea cucumber glycosides as putative anti-cancer agents, and may benefit financially if Frondoside A becomes a drug for human cancers. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SA ODW. Performed the experiments: SA KA AG MAAS TEA. Analyzed the data: SA MB TEA ODW. Contributed reagents/materials/analysis tools: PC TT. Wrote the paper: SA ODW TEA MB TT.